FindTrial
Sign In

Study of CHIP related gene mutations on cardiovascular complications during chemotherapy in patients with acute myeloid leukemia

Study of CHIP related gene mutations on cardiovascular complications during chemotherapy in patients with acute myeloid leukemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059585
Enrollment
Unknown
Registered
2022-05-04
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myelogenous leukemia (AML)

Interventions

CHIP Group:N/A
Control Group:N/A

Sponsors

Shandong University Qilu Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with AML (M2-M5); 2. Aged 16-80 years; 3. Received chemotherapy in our hospital for many times.

Exclusion criteria

Exclusion criteria: 1. Other malignant tumors except blood system; 2. Preleukemia diseases such as MDS\MPN; 3. Severe liver or kidney disease.

Design outcomes

Primary

MeasureTime frame
DNMT3a mutation;JAK2 mutation;ASXL-2 mutation;TP53 mutation;TET2 mutation;—

Countries

China

Contacts

Public ContactWang Zhihao

Shandong University Qilu Hospital

wangzhihaosdu@126.com+86 18560082268

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026